The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2024 | Targeting BAFF-R with CAR-Ts to treat MCL
Mike Barnkob, MD, PhD, Odense University Hospital, Odense, Denmark, shares insights into the development of BAFF-receptor (BAFF-R)-specific CARs, which were investigated for the treatment of mantle cell lymphoma (MCL). While these CARs were able to kill primary MCL cells, relapse did occur, and Dr Barnkob highlights possible escape mechanisms. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy fees: Kite/Gilead, Roche
